Correction: Mobilization studies in mice deficient in sphingosine kinase 2 support a crucial role of the plasma level of sphingosine-1-phosphate in the egress of hematopoietic stem progenitor cells

Mateusz Adamiak; Lakshman Chelvarajan; Kevin R. Lynch; Webster L. Santos; Ahmed Abdel-Latif; Mariusz Z. Ratajczak

doi:10.18632/oncotarget.26195

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Mobilization studies in mice deficient in sphingosine kinase 2 support a crucial role of the plasma level of sphingosine-1-phosphate in the egress of hematopoietic stem progenitor cells

PDF | How to cite

Oncotarget. 2018; 9:34189-34189. https://doi.org/10.18632/oncotarget.26195

Metrics: PDF 1706 views | ?

Mateusz Adamiak^1,2, Lakshman Chelvarajan³, Kevin R. Lynch⁴, Webster L. Santos⁵, Ahmed Abdel-Latif³ and Mariusz Z. Ratajczak^1,2

¹ Stem Cell Institute at James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA
² Department of Regenerative Medicine, Warsaw Medical University, Warsaw, Poland
³ Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY, USA
⁴ Department of Pharmacology University of Virginia, Charlottesville, VA, USA
⁵ Department of Chemistry, Center for Drug Discovery, Virginia Tech, Blacksburg, VA, USA

Published: September 25, 2018

This article has been corrected: The correct Acknowledgments and Funding is provided below:

ACKNOWLEDGMENTS AND FUNDING

This work was supported by NIH grants 2R01 DK074720-10 and R01HL112788, the Stella and Henry Endowment, and the Harmonia NCN grant UMO-2014/14/M/NZ3/00475 to MZR, the Preludium NCN grant UMO-2016/23/N/NZ4/03345 to MA, R01GM121075 to KRL and WLS and the UK COBRE Early Career Program (P20 GM103527) to AAL. MA supported by the Foundation for Polish Science (FNP).

Original article: Oncotarget. 2017; 8:65588-65600. DOI: https://doi.org/10.18632/oncotarget.19514.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26195

Publication Alerts

Corrections:

Correction: Mobilization studies in mice deficient in sphingosine kinase 2 support a crucial role of the plasma level of sphingosine-1-phosphate in the egress of hematopoietic stem progenitor cells